Corcept Therapeutics Investigated for Securities Law Violations Over Misleading Statements.

Corcept Therapeutics Incorporated is under investigation for potential securities law violations. The FDA issued a Complete Response Letter for Corcept's New Drug Application for relacorilant to treat hypertension secondary to hypercortisolism. Corcept's pivotal GRACE trial met its primary endpoint, but the FDA concluded it could not make a favorable benefit-risk assessment without additional information. The investigation focuses on whether the Company issued false or misleading statements or failed to disclose pertinent information.